iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Show more

Location: 321 Arsenal Street, Watertown, MA, 02472, United States | Website: https://www.iteostherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

396.1M

52 Wk Range

$4.80 - $18.13

Previous Close

$10.35

Open

$10.39

Volume

1,164,148

Day Range

$10.25 - $10.39

Enterprise Value

-133.7M

Cash

520.4M

Avg Qtr Burn

-24.89M

Insider Ownership

1.14%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Belrestotug (EOS-448) + Dostarlimab (doublet) Details
Cancer, Non-small cell lung carcinoma

Failed

Discontinued

Failed

Discontinued

Inupadenant (EOS-850) Details
Cancer, Non-small cell lung carcinoma

Failed

Discontinued

Failed

Discontinued

EOS-215 Details
Cancer, Solid tumor/s

Failed

Discontinued